READ THE FULL HCTI RESEARCH REPORT
Healthcare Triangle (NASDAQ: HCTI) is beginning to show tangible evidence that its strategy of transforming from a relatively small healthcare IT services provider into a broader AI-driven technology company is gaining traction. The company’s second-quarter 2026 results, released August 13, provide perhaps the clearest indication yet of that transformation: revenue increased 158% year over year, gross profit jumped 322%, and gross margin expanded substantially. Just as importantly, the businesses acquired earlier this year continued to perform strongly in their second quarter under HCTI ownership, suggesting that the dramatic growth reported in the first quarter was not simply a one-quarter acquisition effect.
HCTI historically built its business around providing technology services to hospitals, health systems, payers, and pharmaceutical/life-sciences companies. Its core capabilities include cloud migration and management, healthcare data analytics, cybersecurity and compliance, interoperability and EHR-related services. Its HITRUST-certified Cloud and Data Platform is marketed through CloudEz and DataEz, providing healthcare customers with an infrastructure designed for the security and regulatory requirements surrounding sensitive healthcare information.
The legacy business currently consists primarily of Software Services and Managed Services and Support. Software Services generated $1.55 million of Q2 revenue and includes strategic consulting, implementation, and software development work. Managed Services and Support generated another $1.27 million and includes post-implementation support and cloud hosting. The latter is strategically important because HCTI is attempting to move its revenue mix away from one-time projects toward recurring managed, platform, and subscription revenue. Management believes this approach can increase customer retention while creating additional opportunities to cross-sell services into existing healthcare relationships.
We believe the most significant change to the company, however, is the addition of Customer Engagement Services following HCTI’s acquisition of Teyame 360 and Datono Mediacion. The acquired operations provide AI-enabled customer acquisition, digital marketing, telemarketing, lead generation, customer support and omnichannel engagement services. They serve financial institutions, insurers, intermediaries, and other customers and bring HCTI both a new revenue stream and technology that can ultimately be integrated with its healthcare offerings.
That acquisition is already having a dramatic financial impact. Customer Engagement Services produced $6.31 million of Q2 revenue, representing approximately 69% of HCTI’s total quarterly revenue. More importantly, the segment produced approximately $1.64 million of gross profit, equivalent to a roughly 26% gross margin. That margin is above HCTI’s historical companywide margin and was the largest contributor to the improvement in consolidated profitability.
We are also encouraged that Teyame continues to grow rather than merely adding a static block of acquired revenue. On August 6, HCTI announced that Teyame had generated as much revenue from one of Spain’s leading health-insurance customers during the first six months of 2026 as it generated from that customer during all of 2025. HCTI now projects approximately €2 million of annual revenue from that relationship. Teyame manages the customer’s omnichannel acquisition strategy by combining AI-powered engagement with direct account management.
HCTI is also building another AI-focused growth platform through its newly created Purpose Health subsidiary. Announced July 27, Purpose Health is designed to target healthcare providers, payers, life-sciences and MedTech companies in the U.S. and internationally with AI infrastructure, agentic-AI applications, advanced data management, cloud platforms, security solutions and managed IT services. HCTI appointed veteran healthcare technology executive Sumit Ganguli as Purpose Health’s Chairman and CEO, with the objective of building higher-margin, multi-year recurring revenue relationships.
The company is also looking beyond software and services. On July 29, HCTI signed a non-binding letter of intent to acquire a 51% interest in Australia’s CosmoInnovations for proposed consideration of approximately $23.5 million. CosmoInnovations operates in MedTech, BeautyTech and consumer health and has more than 25 proprietary technologies, 27 granted international patents and 61 pending patent applications. Its portfolio spans areas including skincare, light therapy, respiratory wellness, oral health, pain management, transdermal delivery and home-based care. Management has indicated that the business has a commercial pipeline targeting more than $50 million of cumulative revenue over the first three years following an acquisition, although investors should recognize that the transaction remains subject to due diligence and definitive agreements and that those revenue figures are targets rather than guarantees.
The second-quarter financial results provide the strongest support for the positive investment thesis. Revenue increased from $3.56 million in Q2 2025 to $9.19 million in Q2 2026, a 158% increase. Gross profit increased even faster, rising 322% from $0.49 million to $2.07 million. As a result, gross margin expanded from just 13.8% to 22.5%, an 870-basis-point improvement.
The six-month comparison is even more striking. Revenue for the first half of 2026 reached $19.05 million compared with $7.26 million during the comparable 2025 period, an increase of 162%. Gross profit climbed 444% to $4.46 million from $0.82 million, while first-half gross margin more than doubled from 11.3% to 23.4%.
There obviously remains some work to do on profitability, which we believe is the next step. HCTI reported a Q2 net loss of approximately $4.4 million versus roughly $1.4 million a year earlier, with general and administrative expense rising sharply to approximately $4.8 million. Some of the increased expense structure accompanies acquisitions, integration, and the company’s broader growth strategy, but reducing corporate overhead relative to revenue will be an important measure of future execution. Encouragingly, the underlying segments are considerably closer to profitability than the consolidated loss initially suggests: Managed Services generated a segment profit before interest, depreciation, and other items, while the Customer Engagement business produced $1.64 million in gross profit and was close to breakeven at the pre-tax segment level.
Overall, HCTI today looks substantially different from the company that entered 2026. The legacy cloud, data, healthcare IT, and managed-services operations remain the foundation, but Teyame and Datono have added a much larger AI-enabled customer-engagement operation; Purpose Health creates a vehicle for pursuing recurring AI and managed-services revenue in healthcare; and the proposed CosmoInnovations transaction could add an entirely new proprietary-product and intellectual-property dimension.
Most importantly, the strategy is beginning to appear in the numbers. Two consecutive quarters of triple-digit revenue growth, a 322% increase in Q2 gross profit, a near doubling of consolidated gross margin versus the prior-year quarter, and continued organic progress at Teyame provide evidence that HCTI’s transformation is moving beyond corporate announcements and into financial results.
For investors willing to accept the risks associated with a micro-cap company, the potential upside lies in our belief that HCTI is still in the early stages of creating a much larger company. The key milestones over the coming quarters will be continued growth from Teyame, progress in converting Purpose Health into meaningful recurring revenue, additional gross margin expansion, better control of corporate expenses and, potentially, completion and successful integration of CosmoInnovations. If management can deliver on those objectives, the sharp improvement in revenue and gross profit seen during the first half of 2026 could represent the beginning rather than the culmination of HCTI’s transformation.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
